Dr Thompson is Associate Professor of Medicine at the University of California, Davis, School of Medicine with a joint appointment in the Departments of Medical Microbiology and Immunology, and Internal Medicine, Division of Infectious Diseases. Dr Thompson specializes in the care of patients with invasive fungal infections and has research interest in fungal diagnostics, host immunogenetics, and translational mycology.
Dr Thompson is a Co-chair of the Mycoses Study Group Education Committee, which is responsible for the dissemination of materials and knowledge to clinicians across the country to improve the care of patients with fungal infections. He has also been appointed to the Coccidioidomycosis Study Group and the Infectious Diseases Society of America (IDSA) Journal Club, providing editorials in the monthly internationally disseminated IDSA Newsletter.
Dr Ostrosky-Zeichner obtained his medical degree from Universidad Nacional Autonoma de Mexico. He completed his internal medicine residency at Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran, and his infectious diseases fellowship at the University of Texas Medical School at Houston and MD Anderson Cancer Center combined fellowship program. He has advanced training and experience in medical mycology and hospital epidemiology. He is currently a professor of medicine and epidemiology, and the director of the Mycology Research Laboratory, as well as the Medical Director for Epidemiology in the Division of Infectious Diseases of the University of Texas Medical School at Houston. He also serves as the associate fellowship program director and medical director for epidemiology for Memorial Hermann Texas Medical Center. He is a fellow of the American College of Physicians, the Infectious Diseases Society of America, and the Society of Healthcare Epidemiology of America. He is an editor for Journal of Antimicrobial Chemotherapy and an editorial board member of Antimicrobial Agents and Chemotherapy, Critical Care Medicine, and Journal of Clinical Microbiology. Dr Ostrosky-Zeichner has published over 100 peer-reviewed articles and actively pursues translational and clinical research in medical mycology and hospital epidemiology. His areas of expertise include: antifungal susceptibility testing, fungal serologies, PK/PD of antifungals, in vivo models of human mycoses, immunology, and clinical trials in prophylaxis and treatment of fungal infections, as well as hospital epidemiology and infection control.
Dr Bow is Professor of the Departments of Internal Medicine and Medical Microbiology Medicine and Infectious Diseases at the University of Manitoba, Winnipeg, and Member in the Sections of Infectious Diseases and Hematology/Oncology at the Department of Internal Medicine, University of Manitoba. He is the Director, Infection Control Services, at CancerCare Manitoba and is a consultant in Infectious Diseases and Hematology/Oncology in the Winnipeg Regional Health Authority. He is an attending physician in the Manitoba Blood and Marrow Transplant Programme based at the Health Sciences Centre, Winnipeg, and at CancerCare Manitoba. In addition, he is Attending Physician in Hematology/Oncology at St. Boniface General Hospital and Health Sciences Centre, Attending Physician in Hematology/Oncology at the Health Sciences Centre, and Attending Physician in Infectious Diseases at the St. Boniface General Hospital and Health Sciences Centre.
Dr Bow graduated from the University of Calgary, and trained in General Internal Medicine, Hematology and Oncology at McMaster University, in Clinical Microbiology at the University of Toronto, and in Infectious Diseases at the University of Manitoba. From June 2009 to November 2012, Dr Bow held the position of Medical Director of the Oncology Programme at the Winnipeg Regional Health Authority. From 1997 to June 2009, he held the positions of Head of the Section of Hematology/Oncology at the University of Manitoba, Health Sciences Centre, and St. Boniface General Hospital; and Head of the Department of Medical Oncology and Hematology at CancerCare Manitoba; also, the position of Director and Chief of Services at the GD6 Oncology Unit in the Health Sciences Centre, Oncology Program, Winnipeg Regional Health Authority from 1990 to June 2009. Dr Bow was the recipient three times of the Clinical Infectious Diseases Award for Outstanding Review. He has published widely and has authored several book chapters.
He is currently a member of several Clinical Practice Guidelines panels, including the Infectious Diseases Society of America, American Society of Clinical Oncology, the Centers for Disease Control and Prevention, and the Association for Medical Microbiology and Infectious Diseases Canada. He is a member of the Steering Committee for the International Mycoses Study Group; a member of the Multinational Association for Supportive Care in Cancer, Mucositis Study Group; and has been a member of Council for the International Immunocompromised Host Society. He is also a member of several professional societies, and a manuscript reviewer on numerous peer-reviewed journals. Dr Bow’s research interests have focused on the prevention and management of bacterial and fungal infections in neutropenic cancer patients and cytotoxic therapy-induced intestinal epithelial damage in the pathogenesis of these infections.
Dr Johnson is a Clinical Pharmacist/Associate Professor of Medicine in the Division of Infectious Diseases & International Health at Duke University Medical Center (DUMC). After obtaining a Bachelor of Science in Biochemistry from the University of Georgia, she completed her Doctor of Pharmacy at Campbell University and a Fellowship in Infectious Diseases Pharmacotherapy at DUMC. She also completed a Masters of Health Science in Clinical Research at Duke University School of Medicine, concentrating on biostatistics and epidemiology. Dr Johnson maintains a clinical practice in infectious diseases at DUMC. Her clinical research interests include invasive fungal infections in immunocompromised hosts with special focus on immunogenetics, pharmacogenetics, and pharmacodynamics. She has served as investigator for numerous clinical trials with antifungal, antiretroviral, and antibacterial agents. She was the recipient of a 5-year NIH/NIAID Mentored Career Award to pursue patient-oriented research in invasive candidiasis, and was co-investigator on an NIH program grant to investigate microfluidic methods of detection for infectious pathogens including Candida spp. Dr Johnson has been an active member of both the DUMC and Durham VAMC Antimicrobial Stewardship programs for 17 years. She has published in numerous peer-reviewed journals, and is a reviewer for Antimicrobial Agents and Chemotherapy, Clinical Infectious Diseases, Pharmacotherapy, and Journal of Antimicrobial Chemotherapy. She also serves as Associate Editor for the journal Frontiers in Public Health. She has been an invited international & national speaker on topics such as antibiotic resistance, HIV, invasive fungal infections, and management of bacterial infections. She is an active member of the American College of Clinical Pharmacy (ACCP), American Society of Microbiology, and Society of Infectious Disease Pharmacists.